Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Article information 1
18 GLP-1 RAs were initially approved by the FDA for the treatment of type 2 diabetes based on phase 3 trials demonstrating superiority in reducing hemoglobin A 1c and improving cardiovascular outcomes compared with other antihyperglycemic medications
Expert Interview Barbie Ritzman
Clinical trials showed blood pressure reductions of 6-8 mmHg systolic on average
How It Works Shake & Spray: Gently shake the bottle, insert the nozzle, and dispense 1-2 sprays per nostril
Leveraging harmonized data from 22 prospective, population-based cohorts within the Global Cardiovascular Risk Consortium, we applied the placebo-adjusted changes in 5 key risk factors as observed in the SELECT trial: BMI (8.5%), HbA 1c (5.5%), systolic blood pressure (2.5%), non-HDL cholesterol (6.0%), and hsCRP (37.8%)
